Inventor

HEIKO SCHUSTER

Inventor

DE

Overview

2021–2026

Patent span

Chemistry

Primary field (CPC C)

Patents· 70 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides20%

A61KPreparations for medical, dental or toiletry purposes20%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%

C12NMicroorganisms or enzymes15%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms10%

G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology7%

C07DHeterocyclic compounds4%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture1%

PatentTitleYear

12,570,760Antigen binding proteins specifically binding PRAME2026 12,480,958Method for the characterization of peptide:MHC binding polypeptides2025 12,318,407Peptides displayed by HLA for use in immunotherapy against different types of cancers2025 12,312,412MAGEB2 binding constructs2025 12,290,530Peptides displayed by HLA for use in immunotherapy against different types of cancers2025 12,285,443Peptides displayed by HLA for use immunotherapy against different types of cancers2025 12,274,716Peptides displayed by HLA for use immunotherapy against different types of cancers2025 12,269,881Antigen binding proteins specifically binding MAGE-A2025 12,257,269Peptides displayed by HLA for use in immunotherapy against different types of cancers2025 12,246,039Peptides displayed by HLA for use in immunotherapy against different types of cancers2025 12,227,556Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods2025 12,202,878Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2025 12,195,506Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2025 12,195,516Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2025 12,162,917B*44 restricted peptides for use in immunotherapy against cancers and related methods2024 12,098,183Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2024 12,084,486Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2024 12,076,379A*03 restricted peptides for use in immunotherapy against cancers and related methods2024 12,065,471B*44 restricted peptides for use in immunotherapy against cancers and related methods2024 12,065,477Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2024 12,060,399Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2024 11,969,464Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers2024 11,957,716Peptides displayed by HLA for use in immunotherapy against different types of cancers2024 11,952,409Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary class2024 11,951,132Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2024 11,945,850B*44 restricted peptides for use in immunotherapy against cancers and related methods2024 11,918,607Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2024 11,919,940Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2024 11,904,003Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers2024 11,891,427Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers2024 11,872,270A*03 restricted peptides for use in immunotherapy against cancers and related methods2024 11,858,978Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2024 11,859,009Antigen binding proteins specifically binding PRAME2024 11,840,577Antigen binding proteins specifically binding MAGE-A2023 11,840,562Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2023 11,833,193A*03 restricted peptides for use in immunotherapy against cancers and related methods2023 11,833,195Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers2023 11,819,518Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers2023 11,806,366Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers2023 11,801,264Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2023 11,779,606Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2023 11,779,605Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods2023 11,732,021Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2023 11,680,089B*44 restricted peptides for use in immunotherapy against cancers and related methods2023 11,667,685B*44 restricted peptides for use in immunotherapy against cancers and related methods2023 11,655,280Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2023 11,655,281Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2023 11,629,177B*44 restricted peptides for use in immunotherapy against cancers and related methods2023 11,603,397Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods2023 11,576,955A*03 restricted peptides for use in immunotherapy against cancers and related methods2023 11,554,164A*03 restricted peptides for use in immunotherapy against cancers and related methods2023 11,433,099Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods2022 11,376,281Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2022 11,369,636Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2022 11,357,797Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2022 11,345,737Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2022 11,278,571Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers2022 11,246,917A*03 restricted peptides for use in immunotherapy against cancers and related methods2022 11,246,889Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers2022 11,248,035Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2022 11,214,608Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2022 11,208,448B*44 restricted peptides for use in immunotherapy against cancers and related methods2021 11,197,892Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2021 11,179,418Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2021 11,155,590B*44 restricted peptides for use in immunotherapy against cancers and related methods2021 11,154,576Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2021 11,147,839Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2021 11,147,838Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2021 11,141,437Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers2021 11,142,556Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2021

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2021–2026Patents assigned to IMMATICS BIOTECHNOLOGIES GMBH (70)· patent assignee history

2021–2026Based in DE· patent location history

2025Patents assigned to AMGEN INC (1)· patent assignee history

2025Patents assigned to AMGEN RES MUNICH GMBH (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMATICS BIOTECHNOLOGIES GMBH	70	2021–2026
AMGEN INC	1	2025
AMGEN RES MUNICH GMBH	1	2025

Locations

Location	Patents	Span
DE	70	2021–2026